BMI-1 Mediates Estrogen-Deficiency-Induced Bone Loss by Inhibiting Reactive Oxygen Species Accumulation and T Cell

Jinbo Li1, Qian Wang2, Renlei Yang1

  • 1State Key Laboratory of Reproductive Medicine, The Research Center for Bone and Stem Cells, Department of Anatomy, Histology and Embryology, Nanjing Medical University, Nanjing, Jiangsu, China.

Insights

Estrogen deficiency causes bone loss by reducing BMI-1, increasing oxidative stress and T cell activation. Restoring BMI-1 in T cells protects against bone loss, clarifying a novel mechanism.

Area of Science:

  • Bone Biology
  • Immunology
  • Oxidative Stress

Background:

  • Estrogen is crucial for bone homeostasis, but the mechanism linking estrogen deficiency to oxidative stress remains unclear.
  • The B lymphoma Mo-MLV insertion region 1 (BMI-1) gene is implicated in oxidative stress protection and regulated by estrogen.
  • Reactive oxygen species (ROS) accumulation is a key factor in estrogen deficiency-induced bone loss.

Purpose of the Study:

  • To investigate the role of BMI-1 in estrogen deficiency-induced bone loss.
  • To elucidate the mechanism by which estrogen deficiency leads to ROS accumulation and T cell activation.
  • To determine if BMI-1 modulation in T cells can prevent bone loss.

Main Methods:

  • Ovariectomized mice were treated with N-acetyl-cysteine (NAC) or control.
  • BMI-1 deficient mice were compared with wild-type (WT) mice, with/without NAC.
  • Transgenic mice overexpressing BMI-1 in lymphocytes were ovariectomized and compared to WT controls.

Main Results:

  • Ovariectomy increased bone loss, ROS, T cell activation, and RANKL, which NAC largely prevented.
  • BMI-1 expression was downregulated in T cells from ovariectomized mice.
  • BMI-1 deficiency mimicked ovariectomy-induced changes, while NAC reversed them; BMI-1 overexpression in lymphocytes prevented bone loss.

Conclusions:

  • Estrogen deficiency downregulates BMI-1, leading to increased ROS, T cell activation, and RANKL production.
  • This cascade enhances osteoclastogenesis and accelerates bone loss.
  • Targeting BMI-1 in T cells represents a novel therapeutic strategy for estrogen deficiency-induced bone loss.